Report

Blockbuster Biologics Review

2018–2024
Biologics

Blockbuster Biologics Review, produced by our intellectual property lawyers, covers developments in inter partes review (IPR) and patent litigation challenges to blockbuster biologic drugs.

These quarterly reports provide updates on the following topics:

  • The current status of IPR challenges to blockbuster biologics
  • The institution and invalidation rates for IPRs challenging blockbuster biologics
  • The current status of patent litigations implicating blockbuster biologics

We will continue to monitor developments and provide updates regularly.

Read the current issue >>

Past Issues

2024

Issue 24 (August 2024) >>

Issue 23 (May 2024) >>

Issue 22 (February 2024) >>

2023

Issue 21 (November 2023) >>

Issue 20 (August 2023) >>

Issue 19 (March 2023) >>

2022

Issue 18 (December 2022) >>

Issue 17 (October 2022) >>

Issue 16 (July 2022) >>

Issue 15 (April 2022) >>

2021

Issue 14 (December 2021) >>

Issue 13 (August 2021) >>

Issue 12 (April 2021) >>

Issue 11 (February 2021) >>

2020

Issue 10 (September 2020) >>

Issue 9 (April 2020) >>

Issue 8 (February 2020) >>

For access to an issue prior to 2020, please contact IPPGBusinessDevelopmentLocal@morganlewis.com.

Additional Resources

News

Thought Leadership